Ask a question

COVID-19 Vaccine Media Hub

A global resource for journalists and fact-checkers, providing a hub for the latest scientific information, expert opinion and evidence-based research on COVID-19 vaccines.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

One-dose Janssen COVID-19 vaccine being approved by the MHRA

It has been announced that the one-dose Janssen COVID-19 vaccine has today been given regulatory approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Safety, immunogenicity and efficacy results from the trial of the Pfizer-BioNTech COVID-19 vaccine in adolescents

A study published in the New England Journal of Medicine (NEJM) looks at safety, immunogenicity, and efficacy results from the Pfizer-BioNtech COVID-19 vaccine trial in children aged 12 to 15.

What are first, second and third waves of infections?

Waves of an illness occur when daily rates of infections increase over time, reach a peak, then decrease more over time. Many different characteristics determine what makes a wave occur in each region but certain aspects remain the same.

Do the Seychelles have the highest global vaccination rate and the biggest COVID-19 surge?

Seychelles has the highest percentage of vaccinated people in the country per capita. Though the nation is dealing with a current surge in cases, it does not have the world's biggest surge in terms of total cases or as a percentage of its population.

NZ scientists to lead largest-ever vaccine monitoring study

A global collaboration helmed in New Zealand will help assess the safety of COVID-19 vaccines on a massive scale. The Global Vaccine Data Network (GVDN) at the University of Auckland, with its 21 partners in 17 countries, has been awarded funds by the US Centers for Disease Control and Prevention (CDC) to monitor 300 million people for vaccine side-effects.

Australian state of Victoria announces 7-day circuit breaker lockdown to combat highly infectious variant of concern

It has just been reported that the state of Victoria, Australia will enter a seven-day circuit breaker lockdown from 11:59pm tonight in a bid to curb the state’s growing coronavirus outbreak caused by a highly infectious variant of concern. In a press conference, Acting Premier James Merlino said there are now 34 active cases of coronavirus in Victoria, with 12 linked new cases in the past day. Mr Merlino said the primary concern is how quickly this strain is moving. The State Government is urging everyone to get vaccinated and has said getting vaccinated will be one of five reasons people are allowed to leave home.

German preprint giving theory about why blood clots might rarely occur after vector-based COVID-19 vaccines

A preprint, an unpublished non-peer reviewed study, from researchers in Germany presents a theory for why vector-based COVID-19 vaccines, such as Oxford-AstraZeneca and Johnson & Johnson, may cause rare blood clots.

Eigenschaften und Verbreitung der SARS-CoV-2-Variante B.1.617.2

Die ursprünglich aus Indien stammende Variante B.1.617.2 des SARS-CoV-2-Virus breitet sich trotz niedriger Inzidenzen weiter in Großbritannien aus. Britische Forschende schätzen, dass sie sich 50 Prozent schneller verbreiten kann als die vorherrschende Variante B.1.1.7. Im Mai wurde sie daher auch von der Weltgesundheitsorganisation als „Variant of Concern“ (VOC) eingestuft, wie zuvor auch schon B.1.1.7. Aufgrund der raschen Verbreitung von B.1.617.2 in Großbritannien beobachten britische Wissenschaftlerinnen und Wissenschaftler die Entwicklung ganz genau, charakterisieren die Variante im Labor und modellieren ihre weitere Verbreitung. Das SMC hat zwei von ihnen gebeten, ihre neuen Erkenntnisse in einem virtuellen Press Briefing zu berichten und Ihre Fragen zu beantworten. Außerdem möchten wir gerne einen Blick in die Zukunft werfen und besprechen, welche potenziellen Varianten anhand des derzeitigen Wissenstandes noch zu erwarten sind und wie diese mit dem Impffortschritt wechselwirken.

Are COVID-19 vaccines causing antibody-dependent enhancement?

As of May 2021, there is no evidence to suggest that COVID-19 vaccines are leading to antibody-dependent enhancement.

Letter presenting three cases of ischaemic stroke following the Oxford-AstraZeneca COVID-19 vaccine

A letter published in the Journal of Neurology Neurosurgery & Psychiatry discusses three cases of ischaemic stroke, blood clots in arteries causing lack of blood supply to part of the brain, reported in young adults after receiving the Oxford–AstraZeneca vaccine.

Moderna press release announcing that its TeenCOVE study of its COVID-19 vaccine in adolescents met its primary endpoint

A press release from Moderna announces the TeenCOVE study of its COVID-19 vaccine in adolescents meets primary endpoint and plans to submit data to regulators in early June.

「輝瑞疫苗疫苗保護力29.5%?」專家意見

一則臉書貼文指出:英國醫學雜誌報導台灣要買的輝瑞疫苗只有29.5%有效率。這個訊息已引起社會關注,對此,我們邀請國家衛生研究院感染症與疫苗研究所副研究員級主治醫師齊嘉鈺,針對以下幾則訊息進行解析: 1.流傳內容稱「根據英國醫學雜誌報導,輝瑞疫苗疫苗保護力為29.5%」。該篇貼文的說法是否正確? 2.輝瑞疫苗的保護效力為何?

PHE on vaccine effectiveness against the B.1.617.2 ‘Indian’ variant

A preprint from Public Health England (PHE) looks at the effectiveness of COVID-19 vaccines against the B.1.617.2 variant first identified in India.

Are vaccine injections emitting electric and magnetic fields?

None of the COVID-19 vaccines approved for emergency use contain any metals or use any radiation technology that would emit high levels of electric and magnetic fields (EMF).

變種病毒疫情與疫苗研究之專家意見

近期台灣疫情升溫,引發大眾擔憂若印度變種病毒進入台灣,是否可能引發更嚴重的傳播疫情,以及懷疑疫苗是否也會因此失去保護力。在5月10日,世界衛生組織(WHO)宣布,在印度被發現的新冠變種病毒「B.1.617」(印度變種),由VOI(值得關注的變異,Variant of Interest),升級為VOC(需留意的變異,Variant of Concern)。世界衛生組織新冠疫情技術總監范科霍芙(Maria van Kerkhove)在記者會中指出:「已經有研究指出B.1.617能夠更輕易人傳人,傳播力更強」。研究顯示「B.1.617」除了傳播力更強,還具有更強的致病能力。

Can people get the COVID-19 vaccine alongside other immunizations?

The United States Centers for Disease Control and Prevention recently stated that they believe it is safe to administer COVID-19 vaccines at the same time as other vaccines. However, vaccines given on the same day should be injected in different areas, there is uncertainty about whether or not giving two or more different vaccines at once may cause worse side effects, or if vaccines containing weakened live viruses might require different guidance. At this time, the World Health Organization has not issued new recommendations for administering different vaccines at the same time as a COVID-19 vaccine, though it has listed the AstraZeneca vaccines for emergency use. This vaccine contains a weakened live pathogen so health regulators may decide if it is safe to administer this vaccine at the same time as others.

Can people receive three jabs of Sinovac's CoronaVac vaccine?

We do not yet know if Sinovac's COVID-19 third dose is safe or effective. A third injection is being tested in a Chinese clinical trial now. It is not recommended to have a third vaccine dose until more data has been studied and it has been deemed safe by health organizations.

What happens if you get an expired vaccine?

Getting any expired vaccine can mean that you are not protected as well or at all from a disease. It’s also possible that certain inactive vaccines could cause harmful reactions, but there are not many documented cases of this happening, and no documented cases of this happening with COVID-19 vaccines. Because COVID-19 manufacturers were very cautious in setting expiration dates, it’s possible that COVID-19 vaccines are effective for a short period of time even after the set expiration date.

Are there microchip technologies that are small enough to pass through a syringe needle and allow people to be tracked?

Are there microchip technologies that are small enough to pass through a syringe needle and allow people to be tracked?

Expert reaction to preprint looking at the immune response in older people after vaccination the Pfizer COVID-19 vaccine with either a 3-week or a 12-week dosing schedule, as posted on MedRxiv

An expert reaction to a preprint looking at the immune response in older people after vaccination the Pfizer COVID-19 vaccine with either a 3-week or a 12-week dosing schedule, as posted on MedRxiv

Verbreitung der SARS-CoV-2-Variante B.1.617 in Europa und Implikationen

Die prekäre COVID-19-Situation in Indien sorgt weiterhin für Schlagzeilen. Dafür verantwortlich gemacht wird die Variante B.1.617 des SARS-CoV-2-Virus, mit der sich dort viele Menschen anstecken. Kürzlich wurde die Untergruppe (Unterklade) der Variante mit der Bezeichnung B.1.617.2 von einer „Variant of Interest“ (VOI) zu einer „Variant of Concern“ (VOC) hochgestuft. Was bedeutet eine zunehmende Verbreitung der neuen Variante?

What is the scientific or public health basis for the new CDC recommendations that fully vaccinated people can go unmasked?

SciLine reaches out to our network of scientific experts and poses commonly asked questions about newsworthy topics. Reporters can use these responses in news stories, with attribution to the expert.

Is dropping mask requirements for the fully vaccinated an effective way to encourage vaccination?

SciLine reaches out to our network of scientific experts and poses commonly asked questions about newsworthy topics. Reporters can use these responses in news stories, with attribution to the expert.

What do we know so far about the Sinopharm vaccine?

Sinopharm's two-dose COVID-19 vaccine was shown to have an efficacy rate of roughly 79% to protect against symptomatic and hospitalized infections. Controversy over the lack of published data about the vaccine has continued despite Sinopharm receiving emergency use authorization from the World Health Organization.

Moderna to supply Australia with 25m doses of COVID-19 vaccine

The Australian Government has confirmed it has secured 25 million doses of the Moderna COVID-19 vaccine, following an announcement from the company overnight. This is the second messenger RNA (mRNA) vaccine to be purchased by the Government, providing access to the current Moderna vaccine or variant-specific versions of the vaccine developed by Moderna, to address emerging viral variants.

No results found.

About the Hub

The COVID-19 Vaccine Media Hub is a dedicated resource for journalists and fact checkers wanting access to evidence-based information on COVID-19 vaccines. The Hub brings together multiple sources of evidence-based information on vaccines, including explainers, expert commentary, the latest research and online press briefings, with material soon to be available in multiple languages.

If you’re a fact checker or a journalist, we’re here to help you find the information and experts you need for your story.

If you’re a member of the public and would like help finding information on COVID-19 vaccines, feel free to browse the site. You might also like to explore other evidence- based vaccine information sites such as the WHO's COVID-19 vaccine page.

This project is a global effort with contributions from Science Media Centres in Australia, the UK, Germany and New Zealand plus technology not-for-profit, Meedan. Other contributors are based in North America, Africa, Latin America and the Asia Pacific region.

The COVID-19 Vaccine Media Hub is supported by the Google News Initiative.

Google News Initiative LogoAustralian Science Media Centre LogoMeedan Logo

Australian Science Media Centre

The Australian Science Media Centre works to enhance the media’s coverage of science, for the benefit of the public. We provide the evidence and experts when science hits the headlines.

Health Desk

Information equity is a public health issue. Health Desk provides rapid responses to health questions from fact-checkers and journalists. We host content about COVID-19 vaccine created by Science Media Centres around the world.

Science Media Center Germany

A non-profit and editorially independent institution that supports journalists in reporting on science-related topics.

UK Science Media Centre

The SMC’s mission is to improve the public understanding of science by ensuring that the news media has easy access to the very best experts and evidence when science hits the headlines.

Science Media Centre NZ

When science meets the headlines, the SMCNZ is there to promote accurate, evidence-based reporting on science, health and technology by helping the media work more closely with the scientific community.

SciLine

SciLine is a philanthropically funded, editorially independent, free service, whose primary mission is to connect U.S. journalists to knowledgeable, articulate scientific experts and science-based resources.

Science Media Centre of Canada

The Science Media Centre of Canada is an independent non-profit that helps journalists and science writers cover science, medical and technology stories that impact the lives of Canadians.

Africa Science Media Centre

AfriSMC was established by ScienceAfrica and Partners in September 2020 in Nairobi, Kenya, to improve the credibility of media reporting of emerging scientific issues, such as the Coronavirus pandemic.

Science Media Center Taiwan

SMC Taiwan was established in 2017, as one of the international SMCs. SMC Taiwan is the only SMC in Asia connecting journalists and scientists to provide evidence-based information through the media. Please contact us if you require any assistance with reporting COVID-19. 關於疫情若需要任何進一步的專家意見,以協助民眾判讀各式科學資訊,都歡迎隨時聯繫我們。 SMC Taiwan是國際科學媒體中心的一員,唯一的亞洲科學家媒體媒合平台,會持續提供專家意見與相關研究討論,給各位媒體朋友們參考。